A forum for researchers, students and applicants in the field of cyclodextrin technology
A β-CDP (CycloLab) was used for the experiments. The purity of the β-CDP was >95 %. The β-CDP contained <1 % of
Cyclodextrins (CDs) have traditionally been recognized as excipients that enhance solubility and stability of drugs. However, growing evidence shows that
Cellular senescence, a hallmark of aging, has been implicated in Alzheimer’s disease (AD) pathogenesis. Cholesterol accumulation is known to drive
Amyloid-β (Aβ) is considered a primary therapeutic target for Alzheimer’s disease (AD). However, just eliminating Aβ in patients with AD
New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer’s
Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM) are two prevalent conditions that present considerable public health issue in
„Short road to discovery, winding road to use” Josef Pitha I assume that many of you remember the “story”
RENATUS, a South Korea-based pharma company pioneering next generation cyclodextrin-based therapies for the safe treatment of cholesterol-associated diseases recently filed
Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of
Li-Huei Tsai, director of Picower Institute for Learning and Memory (Massachusetts Institute of Technology) and her coworkers recently filed a patent
